On Friday, Medidata Solutions Inc (NASDAQ: MDSO) stock plunged -0.1% and closed at 91.87. Its recent trading capacity is 547543 shares versus to its average trading volume of 750224 shares. The company stock lowest price point for the session stood at $91.86. MDSO traded as low as $ 60.1 in the past 52 weeks, and shares hit its peak level to $98.6.
In response to this clear and demonstrated need, Medidata (MDSO) created Study Site Analytics which provides sites with access to standardized performance metrics from sponsors and CROs. The feedback includes metrics for screen failure, early termination, and enrollment. For each metric, Study Site Analytics also provides benchmarks for sites to compare their performance relative to other anonymized sites within a study.
“The SCRS survey emphasizes the overwhelming need for insight into performance metrics and how the industry can and should work together to make the right process improvements,” stated Glen de Vries, co-founder, president, Medidata. “I’m proud to say we’ve delivered a feature that brings key indicators for sites to the front page of their iMedidata dashboards, and enable better alliance with sponsors, ultimately bringing therapies to patients faster.”
Insights alongside performance comparisons enable sites to pinpoint where they are over/under performing. This information allows sites to make informed decisions that improve specific processes and procedures as well as share performance with sponsors for future studies.
“Sites have been requesting access to the important data contained within Medidata’s Site Analytics Dashboard for several years,” stated Casey Orvin, SCRS president. “Years ago, SCRS founder Christine Pierre challenged the Medidata team to create a means to give sites access to bench-marking data on how its site stacks up against others on a given trial. Medidata has met that challenge with the Study Site Analytics Dashboard. With the shift toward digitally powered clinical trials, visibility into this data has never been more important to all parties involved.”
The price moved ahead of 0.99% from the mean of 20 days, 1.08% from mean of 50 days SMA and performed -3.23% from mean of 200 days price. Company’s performance for the week was -0.63%, -0.14% for month and YTD performance remained 9.19%. The stock opened the session at $91.98 and touched its highest price point at $91.99.